Statements (55)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:secukinumab
|
| gptkbp:acquisition |
gptkb:Alcon_(2010)
Ave Xis (2018) The Medicines Company (2020) |
| gptkbp:ceo |
gptkb:Vas_Narasimhan
|
| gptkbp:clinical_trial |
multiple ongoing clinical trials
invests heavily in R& D |
| gptkbp:employees |
approximately 110,000
|
| gptkbp:founded |
gptkb:1996
|
| gptkbp:global_presence |
operates in over 140 countries
|
| gptkbp:headcount |
approximately 110,000
|
| gptkbp:headquarters |
gptkb:Basel
gptkb:Basel,_Switzerland |
| https://www.w3.org/2000/01/rdf-schema#label |
Novartis Pharmaceuticals
|
| gptkbp:industry |
gptkb:drug
|
| gptkbp:market_cap |
$200 billion (2021)
|
| gptkbp:parent_company |
gptkb:Novartis_AG
|
| gptkbp:partnership |
gptkb:physicist
gptkb:Microsoft gptkb:Amgen |
| gptkbp:philanthropy |
gptkb:Novartis_Foundation
|
| gptkbp:products |
prescription medications
|
| gptkbp:research_areas |
endocrinology
metabolic disorders neurology pediatrics rare diseases autoimmune diseases chronic diseases hematology psychiatry dermatology cardiovascular diseases infectious diseases pain management women's health ophthalmology transplantation urology gastroenterology respiratory |
| gptkbp:research_focus |
oncology
immunology cardiovascular |
| gptkbp:revenue |
$48.5 billion (2020)
|
| gptkbp:subsidiary |
gptkb:Alcon
gptkb:Sandoz gptkb:Novartis_Gene_Therapies |
| gptkbp:sustainability |
diversity and inclusion initiatives
environmental responsibility focus on access to medicines |
| gptkbp:symbol |
NVS
|
| gptkbp:website |
www.novartis.com
|